1. Imatinib and dasatinib are both ATP-competitive BCR-ABL1 inhibitors, but they differ in the conformational state of the kinase they recognize. Which statement correctly characterizes imatinib's binding mode and its mechanistic consequence?
A) Imatinib binds only the active conformation of the kinase, which is why it remains effective against most imatinib-resistant mutations
B) Imatinib binds the inactive (DFG-out) conformation of the kinase domain, a conformational requirement that makes it more vulnerable to mutations that destabilize the inactive state
C) Imatinib binds covalently to a cysteine residue, producing irreversible inhibition of BCR-ABL1
D) Imatinib binds an allosteric myristoyl pocket rather than the ATP site, accounting for its activity against T315I
E) Imatinib binds DNA in proliferating cells, explaining its broad activity across multiple leukemias
ANSWER: B
Rationale:
Option B is correct. Imatinib is an ATP-competitive inhibitor that selectively recognizes and binds the inactive, DFG-out conformation of the BCR-ABL1 kinase domain. Because its binding depends on the kinase adopting that specific inactive shape, mutations that destabilize the inactive conformation (or favor the active state) reduce imatinib binding and confer resistance. This conformational selectivity is precisely what distinguishes imatinib from dasatinib, which binds both active and inactive conformations and therefore retains activity against a broader range of mutations.
Option A: Option A is incorrect. Imatinib binds the inactive conformation, not the active one, and it is in fact defeated by many resistance mutations rather than remaining broadly effective against them.
Option C: Option C is incorrect. Imatinib is a reversible, ATP-competitive inhibitor; covalent binding to a cysteine describes irreversible agents such as the pan-ErbB inhibitor afatinib, not imatinib.
Option D: Option D is incorrect. Allosteric binding to the myristoyl pocket describes asciminib, a STAMP inhibitor; imatinib occupies the ATP-binding site.
Option E: Option E is incorrect. Imatinib does not bind DNA. It is a targeted kinase inhibitor, not a DNA-binding cytotoxic agent.
2. Dasatinib and nilotinib are both second-generation BCR-ABL1 TKIs more potent than imatinib, but they differ in conformational binding and off-target kinase activity. Which statement correctly distinguishes dasatinib?
A) Dasatinib is a structurally modified imatinib analog that, like imatinib, binds only the inactive conformation
B) Dasatinib is the only approved TKI with consistent activity against the T315I gatekeeper mutation
C) Dasatinib achieves its activity by allosteric binding to the myristoyl pocket
D) Dasatinib binds both the active and inactive conformations of the kinase and is also a potent SRC-family kinase inhibitor, broadening its activity against most imatinib-resistant mutations except T315I
E) Dasatinib must be taken on an empty stomach because a high-fat meal increases its bioavailability by roughly 80%
ANSWER: D
Rationale:
Option D is correct. Dasatinib's defining mechanistic features are that it binds both the active and inactive conformations of BCR-ABL1 (unlike imatinib, which is restricted to the inactive conformation) and that it is also a potent inhibitor of SRC-family kinases. This dual-conformation binding is the structural basis for its activity against most imatinib-resistant kinase-domain mutations — with the notable exception of T315I, which it does not overcome.
Option A: Option A is incorrect. Nilotinib, not dasatinib, is the structurally modified imatinib analog, and dasatinib binds both conformations rather than only the inactive one.
Option B: Option B is incorrect. Ponatinib (an ATP-competitive agent) is the one with consistent T315I activity; dasatinib does not overcome T315I.
Option C: Option C is incorrect. Allosteric myristoyl-pocket binding describes asciminib; dasatinib is ATP-competitive.
Option E: Option E is incorrect. The strict empty-stomach, high-fat-meal interaction describes nilotinib; dasatinib's key absorption issue is dependence on an acidic gastric environment (reduced by acid suppression), not a fasting requirement.
3. A CML patient harbors the T315I gatekeeper mutation, which defeats imatinib and all second-generation ATP-competitive TKIs. Among the ATP-competitive agents, which drug retains consistent activity against T315I, and what structural feature accounts for it?
A) Ponatinib, because a carbon-carbon triple bond (alkyne) linker in its structure bypasses the steric clash created by the isoleucine substitution at position 315
B) Nilotinib, because its higher potency overcomes the T315I-induced loss of binding affinity
C) Dasatinib, because it binds both the active and inactive kinase conformations
D) Bosutinib, because it simultaneously inhibits SRC and ABL kinases
E) Imatinib, provided the dose is escalated to compensate for reduced affinity
ANSWER: A
Rationale:
Option A is correct. Among the ATP-competitive BCR-ABL1 inhibitors, ponatinib is the one with consistent activity against T315I. It was rationally designed with a carbon-carbon triple bond (alkyne) linker that allows the molecule to accommodate and bypass the steric bulk introduced by the isoleucine substitution at the gatekeeper residue, restoring binding where the other ATP-competitive agents are locked out. (Asciminib also has T315I activity at higher doses, but through a distinct allosteric mechanism rather than as an ATP-competitive agent.)
Option B: Option B is incorrect. Nilotinib's greater potency does not overcome T315I; the mutation sterically and energetically blocks binding regardless of potency.
Option C: Option C is incorrect. Dasatinib's dual-conformation binding broadens its activity against many mutations but specifically not T315I.
Option D: Option D is incorrect. Bosutinib's dual SRC/ABL inhibition does not confer T315I activity.
Option E: Option E is incorrect. Dose escalation does not restore imatinib binding at T315I; the altered pocket prevents binding at any achievable concentration.
4. Asciminib differs mechanistically from every other approved BCR-ABL1 inhibitor. Which statement correctly classifies asciminib and explains the practical advantage of its mechanism?
A) Asciminib is an irreversible ATP-competitive inhibitor that forms a covalent bond within the ATP pocket
B) Asciminib is a second-generation analog of nilotinib that binds the inactive conformation more tightly
C) Asciminib is a STAMP inhibitor that binds the allosteric myristoyl pocket of ABL1 rather than the ATP site, locking the kinase in an inactive conformation, so ATP-pocket mutations such as T315I do not block it
D) Asciminib is a SRC-family kinase inhibitor whose primary target is the SRC pathway rather than ABL1
E) Asciminib inhibits BCR-ABL1 transcription, lowering the amount of fusion protein the cell produces
ANSWER: C
Rationale:
Option C is correct. Asciminib is a STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket). Rather than competing for the ATP site, it binds the myristoyl pocket on the C-terminal lobe of the ABL1 kinase domain and locks the kinase in an inactive conformation through an allosteric mechanism. Because its binding does not depend on the ATP pocket, mutations that defeat ATP-competitive TKIs — including T315I at the appropriate higher dose — do not lock asciminib out. This distinct binding site is the conceptual reason it is valuable in the multiply-resistant setting.
Option A: Option A is incorrect. Asciminib is not an ATP-competitive or covalent ATP-site inhibitor; covalent ATP-site binding describes irreversible agents in other classes.
Option B: Option B is incorrect. Asciminib is not a nilotinib analog and does not act by binding the inactive conformation at the ATP site; it binds a separate allosteric pocket.
Option D: Option D is incorrect. Asciminib's defining target is the ABL1 myristoyl pocket, not the SRC pathway.
Option E: Option E is incorrect. Asciminib inhibits the existing kinase allosterically; it does not act by suppressing transcription of the fusion gene.
5. Each BCR-ABL1 TKI carries a characteristic toxicity that drives its monitoring requirements. Which pairing of agent to its signature toxicity is correct?
A) Imatinib is the agent most strongly associated with pleural effusion, occurring in 20-35% of patients
B) Nilotinib's signature toxicity is acute pancreatitis, mandating lipase monitoring as its principal safety concern
C) Ponatinib's defining safety concern is QTc prolongation requiring serial electrocardiograms after each dose increase
D) Dasatinib's characteristic vascular toxicity is dose-dependent arterial occlusive disease occurring in 25-30% of patients over time
E) Dasatinib is characteristically associated with pleural effusion (and, less often, pulmonary arterial hypertension), while nilotinib is associated with QTc prolongation and arterial occlusive events, and ponatinib with dose-dependent arterial occlusive events
ANSWER: E
Rationale:
Option E is correct. The signature toxicities discriminate the agents: dasatinib characteristically causes pleural effusion (20-35% of patients on standard dosing) and, less commonly, pulmonary arterial hypertension; nilotinib is defined by concentration-dependent QTc prolongation along with peripheral arterial occlusive disease and ischemic cardiovascular events; and ponatinib carries dose-dependent arterial occlusive events in roughly 25-30% of patients over time. Matching each drug to its characteristic toxicity is the basis for their differing monitoring obligations.
Option A: Option A is incorrect. Pleural effusion is the signature toxicity of dasatinib, not imatinib.
Option B: Option B is incorrect. Nilotinib's principal safety concern is QTc prolongation and vascular occlusive events; pancreatic enzyme elevation is more characteristically linked to asciminib.
Option C: Option C is incorrect. Serial-ECG QTc monitoring is the nilotinib requirement; ponatinib's defining concern is arterial occlusive events.
Option D: Option D is incorrect. The dose-dependent arterial occlusive disease (25-30%) describes ponatinib; dasatinib's characteristic toxicity is pleural effusion.
6. Nilotinib and dasatinib each have a clinically critical absorption issue, but the mechanisms are opposite in nature. Which statement correctly discriminates the two?
A) Both drugs require strict fasting because food increases the bioavailability of each by roughly 80%
B) Nilotinib requires strict fasting because a high-fat meal increases its exposure by approximately 80% and its QTc effect is concentration-dependent, whereas dasatinib requires an acidic gastric environment for dissolution, so acid-suppressing drugs reduce its absorption
C) Both drugs require concomitant proton pump inhibitor therapy to achieve reliable absorption
D) Nilotinib's absorption is reduced by acid suppression, whereas dasatinib must be taken on an empty stomach to avoid excessive exposure
E) Neither drug has clinically significant food or gastric-pH interactions, so both can be taken without regard to meals or antacids
ANSWER: B
Rationale:
Option B is correct. The two agents present mirror-image absorption problems. Nilotinib must be taken fasting because a high-fat meal raises its exposure by roughly 80%, and since its QTc-prolonging effect is concentration-dependent, a food-boosted level can become arrhythmogenic. Dasatinib, in contrast, depends on an acidic gastric environment to dissolve, so acid-suppressing agents (especially proton pump inhibitors) markedly reduce its absorption and risk subtherapeutic levels. Distinguishing "food raises nilotinib dangerously" from "acid suppression lowers dasatinib" is the core T1 discrimination here.
Option A: Option A is incorrect. The 80% food effect applies to nilotinib; dasatinib's problem is gastric pH, not a fasting requirement.
Option C: Option C is incorrect. A proton pump inhibitor impairs dasatinib absorption rather than enabling it, and nilotinib's issue is food, not acid.
Option D: Option D is incorrect. This reverses the two drugs: acid suppression affects dasatinib, and the empty-stomach requirement belongs to nilotinib.
Option E: Option E is incorrect. Both drugs have clinically important interactions — food for nilotinib and gastric pH for dasatinib — so neither can be dosed without regard to these factors.
7. Not all EGFR mutations predict the same response to EGFR TKIs. Which statement correctly discriminates among the EGFR alterations encountered in NSCLC?
A) Exon 19 deletions and L858R are uncommon resistant mutations, whereas exon 20 insertions are the common sensitizing mutations
B) L858R and T790M are the two classic sensitizing mutations that predict first-line TKI response
C) All EGFR mutations, including exon 20 insertions, respond comparably to standard first-line EGFR TKIs
D) Exon 19 deletions (del19) and the L858R point mutation are the two common sensitizing mutations that together account for roughly 85% of EGFR-mutant NSCLC and predict TKI response, whereas exon 20 insertions are largely resistant to standard EGFR TKIs
E) Exon 20 insertions are the most common sensitizing mutation and define the patients most likely to benefit from osimertinib
ANSWER: D
Rationale:
Option D is correct. The two common sensitizing EGFR mutations are exon 19 deletions (del19, ~45%) and the L858R point mutation in exon 21 (~40%); together they make up roughly 85% of EGFR-mutant NSCLC and reliably predict response to EGFR TKIs. In sharp contrast, exon 20 insertions are largely resistant to standard EGFR TKIs (including osimertinib at approved doses) and are managed as a distinct molecular subtype. Discriminating sensitizing from resistant EGFR alterations is the essential T1-level distinction.
Option A: Option A is incorrect. It inverts the truth: del19 and L858R are the common sensitizing mutations, while exon 20 insertions are the resistant ones.
Option B: Option B is incorrect. T790M is an acquired resistance mutation, not a baseline sensitizing mutation; the classic sensitizing pair is del19 and L858R.
Option C: Option C is incorrect. Exon 20 insertions specifically do not respond comparably to standard first-line EGFR TKIs.
Option E: Option E is incorrect. Exon 20 insertions are uncommon and resistant, not the most common sensitizing mutation, and they are not the population that benefits from standard osimertinib dosing.
8. Afatinib differs fundamentally from gefitinib and erlotinib in how it engages the EGFR kinase. Which statement correctly characterizes afatinib?
A) Afatinib is an irreversible (covalent) pan-ErbB inhibitor that permanently inactivates EGFR, HER2, and HER4 by forming a covalent bond with cysteine 797 in the kinase domain
B) Afatinib is a reversible, ATP-competitive inhibitor selective for wild-type EGFR over mutant EGFR
C) Afatinib is a third-generation agent designed specifically to target the T790M resistance mutation while sparing wild-type EGFR
D) Afatinib is an allosteric inhibitor that binds outside the ATP pocket and therefore retains activity against all resistance mutations
E) Afatinib selectively inhibits ALK and ROS1 in addition to EGFR, making it a multi-target agent for rearranged NSCLC
ANSWER: A
Rationale:
Option A is correct. Afatinib is a second-generation, irreversible (covalent) pan-ErbB inhibitor. It forms a covalent bond with cysteine 797 in the kinase domain, permanently inactivating EGFR along with the related HER2 and HER4 receptors. This irreversible covalent mechanism distinguishes it from the reversible, ATP-competitive first-generation agents gefitinib and erlotinib, and underlies both its broader ErbB-family coverage and its more pronounced on-target dermatologic and gastrointestinal toxicity.
Option B: Option B is incorrect. Afatinib is irreversible and covalent (not reversible), and EGFR TKIs as a class are selective for mutant over wild-type EGFR, not the reverse.
Option C: Option C is incorrect. The third-generation, T790M-directed, wild-type-sparing agent is osimertinib; afatinib does not overcome T790M.
Option D: Option D is incorrect. Afatinib binds the ATP-site cysteine covalently; it is not an allosteric inhibitor, and it does not retain activity against all resistance mutations (notably T790M).
Option E: Option E is incorrect. Afatinib targets the ErbB/HER family; ALK and ROS1 activity describes agents such as crizotinib and entrectinib, not afatinib.
9. The T790M mutation in EGFR is the most common acquired resistance mechanism to first- and second-generation EGFR TKIs. Which statement correctly describes how T790M causes resistance and how osimertinib was designed to address it?
A) T790M abolishes EGFR kinase activity, so resistance reflects loss of the drug target rather than altered binding
B) T790M is a solvent-front mutation that increases drug efflux from the cell, lowering intracellular drug concentration
C) T790M is a gatekeeper-region mutation that restores the mutant kinase's affinity for ATP and introduces steric hindrance impairing first-generation drug binding; osimertinib was designed to bind both the primary sensitizing mutation and T790M while relatively sparing wild-type EGFR
D) T790M prevents covalent bond formation by osimertinib, which is why osimertinib is ineffective against it
E) T790M is a germline mutation present before treatment that predicts primary resistance to all EGFR TKIs
ANSWER: C
Rationale:
Option C is correct. T790M is a gatekeeper-region substitution that confers resistance by two linked effects: it restores the mutant kinase's affinity for ATP (so ATP outcompetes the drug) and it introduces steric hindrance that impairs binding of first- and second-generation agents. Osimertinib, a third-generation irreversible EGFR TKI, was specifically engineered to inhibit the receptor carrying both the primary sensitizing mutation and T790M, while relatively sparing wild-type EGFR — which also accounts for its milder on-target toxicity.
Option A: Option A is incorrect. T790M does not abolish kinase activity; the kinase remains active, and resistance arises from altered drug binding plus restored ATP affinity.
Option B: Option B is incorrect. T790M is a gatekeeper-region mutation acting on binding/ATP affinity, not a solvent-front efflux mechanism.
Option D: Option D is incorrect. The mutation that prevents osimertinib's covalent bond is C797S (an acquired resistance mechanism to osimertinib), not T790M; osimertinib is in fact effective against T790M.
Option E: Option E is incorrect. T790M is typically an acquired mutation emerging under treatment pressure, not a pre-existing germline marker of primary resistance.
10. Osimertinib's toxicity profile differs from that of first-generation EGFR TKIs in a way that follows directly from its relative sparing of wild-type EGFR. Which statement correctly characterizes this difference?
A) Osimertinib produces more severe acneiform rash and diarrhea than first-generation agents because of stronger wild-type EGFR inhibition
B) Because osimertinib relatively spares wild-type EGFR, it causes less severe dermatologic and gastrointestinal toxicity than first-generation agents, but it introduces agent-specific risks of reduced left ventricular ejection fraction and QTc prolongation
C) Osimertinib has no characteristic toxicities and requires no baseline cardiac assessment
D) Osimertinib's principal toxicity is pleural effusion, mirroring that of dasatinib
E) Osimertinib causes more severe interstitial lung disease than any other agent and is contraindicated in all patients with prior lung disease
ANSWER: B
Rationale:
Option B is correct. Much of the on-target dermatologic and gastrointestinal toxicity of EGFR TKIs comes from inhibition of wild-type EGFR in skin and gut. Because osimertinib relatively spares wild-type EGFR, it produces less severe rash and diarrhea than first-generation agents. However, it carries its own agent-specific risks: a reduction in left ventricular ejection fraction (thought to reflect off-target ErbB4 inhibition in cardiomyocytes) and QTc prolongation, which is why baseline and follow-up cardiac assessment is appropriate. This trade-off — milder on-target effects but added cardiac monitoring — is the key discrimination.
Option A: Option A is incorrect. Osimertinib causes less, not more, rash and diarrhea, precisely because it spares wild-type EGFR.
Option C: Option C is incorrect. Osimertinib does have characteristic toxicities (LVEF reduction, QTc prolongation), and baseline cardiac evaluation is recommended.
Option D: Option D is incorrect. Pleural effusion is the signature toxicity of dasatinib, not osimertinib.
Option E: Option E is incorrect. While ILD is a class concern for EGFR TKIs, it is not uniquely most severe with osimertinib, and osimertinib is not categorically contraindicated in all patients with prior lung disease.
11. After progression on osimertinib, the tertiary EGFR mutation C797S can emerge. Its clinical impact depends on its spatial relationship (cis versus trans) to T790M on the EGFR allele. Which statement correctly describes C797S and this relationship?
A) C797S restores wild-type EGFR function, eliminating the oncogenic driver and producing spontaneous remission
B) C797S is identical in mechanism to T315I in BCR-ABL1 and is overcome by ponatinib
C) C797S increases osimertinib's covalent binding affinity, paradoxically improving response
D) C797S is a solvent-front mutation in ALK, not a relevant EGFR resistance mechanism
E) C797S prevents osimertinib from forming its covalent bond with the kinase; when C797S occurs in cis with T790M (and del19) it confers resistance to all approved EGFR TKIs, whereas when it occurs in trans with T790M a combination of a first-generation TKI plus osimertinib can overcome resistance
ANSWER: E
Rationale:
Option E is correct. C797S substitutes the cysteine residue that osimertinib relies on to form its covalent bond, so the drug can no longer covalently anchor to the kinase. The cis-versus-trans configuration relative to T790M is clinically decisive: when C797S and T790M lie in cis (on the same allele, alongside del19), the tumor is resistant to all approved EGFR TKIs; when they lie in trans (on separate alleles), a combination of a first-generation TKI plus osimertinib can overcome the resistance. This allelic-configuration distinction is a precise T1-level discrimination.
Option A: Option A is incorrect. C797S does not restore wild-type function or remove the driver; it is a resistance mutation.
Option B: Option B is incorrect. Although both are drug-binding-site resistance mutations, C797S is an EGFR mutation not addressed by ponatinib (a BCR-ABL1 agent); the analogy does not extend to ponatinib therapy.
Option C: Option C is incorrect. C797S abolishes the covalent bond rather than enhancing binding; it reduces, not improves, osimertinib efficacy.
Option D: Option D is incorrect. C797S is an EGFR resistance mutation; the ALK solvent-front mutation is G1202R (and ROS1 G2032R), a different setting.
12. Crizotinib and alectinib are both ALK inhibitors, but they differ markedly in CNS penetration and resistance coverage. Which statement correctly discriminates the two agents?
A) Crizotinib has excellent CNS penetration, which is why CNS progression is rare on crizotinib therapy
B) Alectinib is the first-generation ALK inhibitor, while crizotinib is the more selective, more CNS-penetrant second-generation agent
C) Both agents have equivalent CNS penetration, so the choice between them is based solely on cost
D) Crizotinib penetrates the CNS poorly and also inhibits MET and ROS1, so CNS progression is a dominant failure mode; alectinib is a more selective ALK inhibitor with high CNS penetration that overcomes most crizotinib-resistant ALK mutations
E) Crizotinib is more selective for ALK than alectinib and produces fewer off-target effects because it inhibits no other kinases
ANSWER: D
Rationale:
Option D is correct. Crizotinib was the first ALK inhibitor and also inhibits MET and ROS1, but it penetrates the CNS very poorly, so CNS progression becomes a dominant mode of failure even when systemic disease is controlled. Alectinib is a more selective and more potent ALK inhibitor that achieves high CNS concentrations and overcomes most crizotinib-resistant ALK kinase-domain mutations — the combination of properties that displaced crizotinib as a preferred first-line agent.
Option A: Option A is incorrect. Crizotinib's CNS penetration is poor, which is exactly why CNS progression is common on it.
Option B: Option B is incorrect. It reverses the generations: crizotinib is first-generation; alectinib is the more selective, more CNS-penetrant later-generation agent.
Option C: Option C is incorrect. The agents differ substantially in CNS penetration; the choice is driven by efficacy and CNS coverage, not cost alone.
Option E: Option E is incorrect. Crizotinib is less selective (it also inhibits MET and ROS1), not more selective with no off-target kinase activity.
13. Lorlatinib is a third-generation ALK inhibitor with a distinctive resistance-coverage and toxicity profile. Which statement correctly characterizes it?
A) Lorlatinib is a first-generation ALK inhibitor whose principal limitation is poor CNS penetration
B) Lorlatinib was designed to overcome resistance to second-generation ALK TKIs, including the G1202R solvent-front mutation, and is characterized by CNS adverse effects (cognitive and mood changes) and near-universal hypercholesterolemia
C) Lorlatinib's signature toxicity is pleural effusion, paralleling that of dasatinib
D) Lorlatinib has no CNS penetration and therefore cannot treat brain metastases
E) Lorlatinib is an EGFR inhibitor used for T790M-mutant lung cancer
ANSWER: B
Rationale:
Option B is correct. Lorlatinib is a third-generation ALK inhibitor engineered to overcome resistance to second-generation agents, including the G1202R solvent-front mutation that defeats alectinib and brigatinib, and it achieves excellent CNS penetration. Its characteristic toxicities are CNS adverse effects — cognitive impairment and mood changes — occurring in a meaningful minority of patients, and hypercholesterolemia, which develops in nearly all patients and commonly requires statin therapy. These features distinguish it from earlier ALK agents.
Option A: Option A is incorrect. Lorlatinib is third-generation with excellent (not poor) CNS penetration.
Option C: Option C is incorrect. Pleural effusion is dasatinib's signature toxicity, not lorlatinib's.
Option D: Option D is incorrect. Lorlatinib penetrates the CNS very well and is effective against brain metastases.
Option E: Option E is incorrect. Lorlatinib targets ALK (and ROS1), not EGFR; the T790M-directed EGFR agent is osimertinib.
14. Brigatinib, a second-generation ALK inhibitor, carries an agent-specific early adverse event that distinguishes it from other ALK TKIs. Which statement correctly identifies it?
A) Brigatinib characteristically causes hypercholesterolemia in nearly all patients within the first week
B) Brigatinib's signature early toxicity is QTc prolongation requiring an electrocardiogram after every dose
C) Brigatinib can cause an early-onset pulmonary toxicity — dyspnea and hypoxia typically within the first 7 days of therapy — that requires early dose interruption
E) Brigatinib's defining early toxicity is severe acneiform rash from wild-type EGFR inhibition
ANSWER: C
Rationale:
Option C is correct. Brigatinib's distinguishing adverse event is an early-onset pulmonary toxicity presenting as dyspnea and hypoxia, characteristically within the first 7 days of therapy in a small percentage of patients. Recognition matters because it requires prompt dose interruption, and its early timing helps distinguish it from later drug-induced interstitial lung disease. This early pulmonary event is the agent-specific feature that sets brigatinib apart from the other ALK inhibitors.
Option A: Option A is incorrect. Near-universal hypercholesterolemia is characteristic of lorlatinib, not brigatinib's early pulmonary event.
Option B: Option B is incorrect. Serial-ECG QTc monitoring is most associated with agents such as nilotinib; it is not brigatinib's signature early toxicity.
Option D: Option D is incorrect. Pleural effusion is the signature toxicity of dasatinib.
Option E: Option E is incorrect. Severe acneiform rash from wild-type EGFR inhibition is an EGFR-TKI class effect (most pronounced with afatinib), not a brigatinib feature.
15. A treatment-naive patient has ALK-positive NSCLC with asymptomatic brain metastases. Randomized first-line data comparing a CNS-penetrant second-generation ALK inhibitor against crizotinib showed markedly superior progression-free survival and CNS control with the more CNS-penetrant agent. Applying these findings, which choice and rationale is most appropriate for this patient?
A) Choose alectinib (a CNS-penetrant ALK inhibitor) first-line, because its high CNS concentrations control the brain metastases and delay CNS progression, yielding longer progression-free survival than crizotinib in this exact setting
B) Choose crizotinib first-line, because its poor CNS penetration is adequate for asymptomatic brain lesions and it was approved first
C) Defer all systemic therapy and treat with whole-brain radiation alone, since ALK inhibitors do not affect CNS disease
D) Choose an EGFR TKI such as osimertinib, since it has the best CNS penetration of any targeted agent regardless of the driver mutation
E) Choose imatinib, because its broad kinase activity covers ALK-rearranged disease
ANSWER: A
Rationale:
Option A is correct. The clinically actionable lesson from the first-line randomized comparison is application, not recall: in a treatment-naive ALK-positive patient — especially one with brain metastases — the CNS-penetrant agent (alectinib) is preferred because its high CNS concentrations both treat existing brain lesions and delay CNS progression, producing substantially longer progression-free survival than crizotinib. The patient's asymptomatic brain metastases make CNS penetration the decisive selection factor.
Option B: Option B is incorrect. Crizotinib's poor CNS penetration makes it a worse choice precisely when brain metastases are present; prior approval date does not justify selecting an inferior agent.
Option C: Option C is incorrect. CNS-penetrant ALK inhibitors do control CNS disease and can often spare upfront whole-brain radiation in asymptomatic patients; radiation alone is not the appropriate first move.
Option D: Option D is incorrect. Osimertinib targets EGFR-mutant disease; it is not indicated for an ALK-driven tumor regardless of its CNS penetration.
Option E: Option E is incorrect. Imatinib targets BCR-ABL1/KIT/PDGFRA, not the ALK fusion, and has no role in ALK-positive NSCLC.
16. ROS1 fusions define a small subset of NSCLC with its own targeted agents and resistance pattern. Which statement correctly characterizes ROS1-directed therapy and its dominant resistance mutation?
A) ROS1 fusions are treated exclusively with EGFR TKIs such as osimertinib, since ROS1 and EGFR share an identical kinase domain
B) No targeted agents have activity against ROS1 fusions, so platinum chemotherapy is the only option
C) Imatinib is the preferred ROS1-directed agent because it inhibits ROS1 as potently as BCR-ABL1
D) ROS1 fusions are resistant to all kinase inhibitors and behave like exon 20 insertion EGFR disease
E) Crizotinib and entrectinib both have substantial activity against ROS1 fusions (with entrectinib offering superior CNS penetration), and repotrectinib is active against the ROS1 G2032R solvent-front mutation that is the dominant resistance mechanism after a prior ROS1 TKI
ANSWER: E
Rationale:
Option E is correct. ROS1 fusions (most commonly CD74-ROS1) are targetable: crizotinib has substantial activity, and entrectinib is an approved first-line option with superior CNS penetration to crizotinib. After progression on a ROS1 TKI, the dominant resistance mechanism is the ROS1 G2032R solvent-front mutation, against which repotrectinib demonstrates activity. This agent-and-resistance mapping is the precise T1-level distinction for ROS1-positive disease.
Option A: Option A is incorrect. ROS1 fusions are not treated with EGFR TKIs; ROS1 and EGFR are distinct kinases with distinct inhibitors.
Option B: Option B is incorrect. Effective ROS1-targeted agents exist (crizotinib, entrectinib, repotrectinib), so chemotherapy is not the only option.
Option C: Option C is incorrect. Imatinib is not a ROS1-directed agent; the active drugs are crizotinib, entrectinib, and repotrectinib.
Option D: Option D is incorrect. ROS1 fusions are sensitive to targeted therapy, unlike the largely TKI-resistant exon 20 insertion EGFR disease.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.